Oncogene-induced TIM-3 ligand expression dictates susceptibility to anti–TIM-3 therapy in mice
Journal of Clinical Investigation · 15.08.2024 · 134 (16)
DOI: 10.1172/jci177460 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Investigation, online erschienen am 25.06.2024. Verfasst von Nana Talvard-Balland und 41 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine I, Faculty of Medicine and Medical Center. Hauptthemen laut MEDLINE: Hepatitis A Virus Cellular Receptor 2. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 69 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NIAID NIH HHS, NHLBI NIH HHS.
Abstract (Originalsprache)
Leukemia relapse is a major cause of death after allogeneic hematopoietic cell transplantation (allo-HCT). We tested the potential of targeting T cell (Tc) immunoglobulin and mucin-containing molecule 3 (TIM-3) for improving graft-versus-leukemia (GVL) effects. We observed differential expression of TIM-3 ligands when hematopoietic stem cells overexpressed certain oncogenic-driver mutations. Anti–TIM-3 Ab treatment improved survival of mice bearing leukemia with oncogene-induced TIM-3 ligand expression. Conversely, leukemia cells with low ligand expression were anti–TIM-3 treatment resistant. In vitro, TIM-3 blockade or genetic deletion in CD8 + Tc enhanced Tc activation, proliferation, and IFN-γ production while enhancing GVL effects, preventing Tc exhaustion, and improving Tc cytotoxicity and glycolysis in vivo. Conversely, TIM-3 deletion in myeloid cells did not affect allogeneic Tc proliferation and activation in vitro, suggesting that anti–TIM-3 treatment–mediated GVL effects are Tc induced. In contrast to anti–programmed cell death protein 1 (anti–PD-1) and anti–cytotoxic T lymphocyte–associated protein 4 (anti–CTLA-4) treatment, anti–TIM-3-treatment did not enhance acute graft-versus-host disease (aGVHD). TIM-3 and its ligands were frequently expressed in acute myeloid leukemia (AML) cells of patients with post–allo-HCT relapse. We decipher the connections between oncogenic mutations found in AML and TIM-3 ligand expression and identify anti–TIM-3 treatment as a strategy for enhancing GVL effects via metabolic and transcriptional Tc reprogramming without exacerbation of aGVHD. Our findings support clinical testing of anti–TIM-3 Ab in patients with AML relapse after allo-HCT.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine I, Faculty of Medicine and Medical Center.
- CIBSS-Centre for Integrative Biological Signalling Studies, and.
- Faculty of Biology, University of Freiburg, Freiburg, Germany.
- Gene Lay Institute of Immunology and Inflammation, Brigham and Women's Hospital, Massachusetts General Hospital, and Harvard Medical School, Boston, Massachusetts, USA.
- Department of Biomedicine, University of Basel and University Hospital of Basel, Basel, Switzerland.
- Department of Medical Oncology, Dana-Farber Cancer Institute, and Harvard Medical School, Boston, Massachusetts, USA.
Förderung
- NCI NIH HHS
- NIAID NIH HHS
- NHLBI NIH HHS
- European Research Council
- Deutsche Forschungsgemeinschaft
- Leukemia and Lymphoma Society
- National Institutes of Health
- Swiss National Science Foundation
Zitieren
APA
Talvard-Balland, N., Braun, L. M., Dixon, K. O., Zwick, M., Engel, H., Hartmann, A., Duquesne, S., Penter, L., Andrieux, G., Rindlisbacher, L., Acerbis, A., Ehmann, J., Köllerer, C., Ansuinelli, M., Rettig, A., Moschallski, K., Apostolova, P., Brummer, T., Illert, A. L., …, & Zeiser, R. (2024). Oncogene-induced TIM-3 ligand expression dictates susceptibility to anti–TIM-3 therapy in mice. Journal of Clinical Investigation, 134(16). https://doi.org/10.1172/jci177460
Vancouver
Talvard-Balland N, Braun LM, Dixon KO, Zwick M, Engel H, Hartmann A, et al. Oncogene-induced TIM-3 ligand expression dictates susceptibility to anti–TIM-3 therapy in mice. Journal of Clinical Investigation. 2024;134(16). doi:10.1172/jci177460
BibTeX
@article{TalvardBalland2024,
author = {Talvard-Balland, Nana and Braun, Lukas M and Dixon, Karen O and Zwick, Melissa and Engel, Helena and Hartmann, Alina and Duquesne, Sandra and Penter, Livius and Andrieux, Geoffroy and Rindlisbacher, Lukas and Acerbis, Andrea and Ehmann, Jule and Köllerer, Christoph and Ansuinelli, Michela and Rettig, Andres and Moschallski, Kevin and Apostolova, Petya and Brummer, Tilman and Illert, Anna L and Schramm, Markus A and Cheng, Yurong and Köttgen, Anna and Duyster, Justus and Menssen, Hans D and Ritz, Jerome and Blazar, Bruce R and Boerries, Melanie and Schmitt-Gräff, Annette and Sariipek, Nurefsan and Van Galen, Peter and Buescher, Joerg M and Cabezas-Wallscheid, Nina and Pahl, Heike L and Pearce, Erika L and Soiffer, Robert J and Wu, Catherine J and Vago, Luca and Becher, Burkhard and Köhler, Natalie and Wertheimer, Tobias and Kuchroo, Vijay K and Zeiser, Robert},
title = {Oncogene-induced TIM-3 ligand expression dictates susceptibility to anti–TIM-3 therapy in mice},
journal = {Journal of Clinical Investigation},
year = {2024},
volume = {134},
number = {16},
doi = {10.1172/jci177460}
}
EUVIMED